BioSig Resumes Clinical Activities with PURE EP System
May 01 2020 - 10:39AM
- Clinical support staff to return to perform elective
procedures at Texas Cardiac Arrhythmia Institute as of May 4,
2020
- Company reconfirms its commitment to commercial
installations this year
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing a
proprietary biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals, today announced that it plans to resume its
clinical activities following the gradual return to elective
procedures across the nation.
The Company’s clinical team is due to resume patient cases at
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in
Austin, TX, as of May 4, 2020 and is in active discussions with a
number of other centers of excellence regarding the continuation of
its clinical activities and initiation of new installations of PURE
EP(tm) System.
“Our return to supporting cases is an important step for BioSig,
and we have positioned ourselves for a strong transition back. We
analyzed a tremendous amount of clinical data, conducted training
and initiated a number of important physician engagement activities
over the past two months. We now look forward to building on
this work in the clinical setting and bringing PURE signals to more
patients and physicians,” commented Julie Stephenson, BSN, MBA,
Vice President of Clinical Affairs.
“The current pandemic had a profound impact on patients with
cardiac arrhythmias, whose already debilitating conditions were
likely to worsen due to cancellation or postponement of elective
procedures. We sincerely appreciate the commitment of our physician
collaborators, who continued to put patient needs first during
these challenging times. We are grateful to be back in the field
and to help the hospitals care for their patients,” commented
Kenneth L. Londoner, Chairman and CEO of BioSig Technologies,
Inc.
The Company initiated its first clinical trial in November 2019,
and currently enrolls patients at Texas Cardiac Arrhythmia
Institute at St. David’s Medical Center and Mayo Clinic’s Florida
campus. Earlier in 2019 the Company conducted observational patient
cases at Indiana University School of Medicine, Greenville Memorial
Hospital, Santa Barbara Cottage Hospital and Texas Cardiac
Arrhythmia Institute at St. David’s Medical Center. The Company’s
PURE EP(tm) System was used in over 120 procedures on patients with
persistent atrial fibrillation, ischemic ventricular tachycardias,
PVC, atypical flutters and other types of complex arrhythmias.
The Company’s recent Shareholder Letter stated the Company’s
commitment to expanding its clinical footprint and seeking to
convert first commercial proposals to sales in 2020.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).The Company’s first product, PURE EP(tm)
System is a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024